| Identification | Back Directory | [Name]
Labetuzumab Govitecan | [CAS]
1469876-18-3 | [Synonyms]
IMMU130
IMMU-130
IMMU 130
hMN14-SN38
Labetuzumab-SN38
Labetuzumab Govitecan
Labetuzumab govitecan (anti-CEACAM5) |
| Hazard Information | Back Directory | [Uses]
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3]. | [in vivo]
Labetuzumab govitecan (total of 1.0 mg, i.p.) prolongs median survival of GW-39 lung metastatic mouse model[2].
Labetuzumab govitecan (25 mg/kg, i.p., twice weekly for 4 weeks) prolongs median survival of sc LS174T Xenograft in nude mice[2].
| Animal Model: | sc LS174T Xenograft in nude mice | | Dosage: | 25 mg/kg | | Administration: | i.p. twice weekly for 4 weeks | | Result: | Prolonged median survival. |
| Animal Model: | LS174T tumor xenograft model in nude mice (PK assay) | | Dosage: | 0.25 mg | | Administration: | i.v. | | Result: | T1/2: 112.5 h; Cmax: 115 μg/mL; MRT: 147 h. |
| [References]
[1] Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. DOI:10.1200/JCO.2017.73.9011
[2] Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47. DOI:10.1021/mp5006195
[3] Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20. DOI:10.1186/s13045-021-01035-z |
|
| Company Name: |
bioleaper
|
| Tel: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
|